Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Apr;17(4):667-74.
doi: 10.1038/mt.2009.1. Epub 2009 Feb 17.

Optimized lentiviral vector design improves titer and transgene expression of vectors containing the chicken beta-globin locus HS4 insulator element

Affiliations

Optimized lentiviral vector design improves titer and transgene expression of vectors containing the chicken beta-globin locus HS4 insulator element

Hideki Hanawa et al. Mol Ther. 2009 Apr.

Abstract

Hematopoietic cell gene therapy using retroviral vectors has achieved success in clinical trials. However, safety issues regarding vector insertional mutagenesis have emerged. In two different trials, vector insertion resulted in the transcriptional activation of proto-oncogenes. One strategy for potentially diminishing vector insertional mutagenesis is through the use of self-inactivating lentiviral vectors containing the 1.2-kb insulator element derived from the chicken beta-globin locus. However, use of this element can dramatically decrease both vector titer and transgene expression, thereby compromising its practical use. Here, we studied lentiviral vectors containing either the full-length 1.2-kb insulator or the smaller 0.25-kb core element in both orientations in the partially deleted long-terminal repeat. We show that use of the 0.25-kb core insulator rescued vector titer by alleviating a postentry block to reverse transcription associated with the 1.2-kb element. In addition, in an orientation-dependent manner, the 0.25-kb core element significantly increased transgene expression from an internal promoter due to improved transcriptional termination. This element also demonstrated barrier activity, reducing variability of expression due to position effects. As it is known that the 0.25-kb core insulator has enhancer-blocking activity, this particular insulated lentiviral vector design may be useful for clinical application.

PubMed Disclaimer

Figures

<b>Figure 1</b>
Figure 1
Schematic diagrams and gene expression levels of lentiviral vectors containing various cHS4 1.2- or 0.25-kb core insulator configurations. (a) Schematic diagrams of the parental and cHS4 insulator vectors. The 1.2-kb cHS4 insulator was inserted into the SIN-LTR [INS1(+) and INS1(−)] or between enhanced green fluorescent protein (EGFP) cDNA and the 3′LTR [INS2(+) and INS2(−)]. The horizontal arrows indicate the original direction of the insulator elements relative to the chicken β-globin genes. (b–d) HeLa and 293T cells were transduced at a multiplicity of infection (MOI) of 0.1, and K562 cells were transduced with the various vectors at an MOI of 0.4 in triplicate. Mean fluorescence intensity (MFI) and coefficient of variation (CV) values of the EGFP-positive fraction of each cell line are shown with the indicated vectors. The error bar indicates SEM. *P < 0.05, **P < 0.005. (e) Southern blot analysis of DNA from 293T cells transduced with the parental vector or the parental vector containing the 0.25 kb × 2 insulator element, as indicated. P = plasmid, V = vector. DNA was digested with AflII as shown, and probe with an EGFP probe. LTR, long-terminal repeat; MSCV, murine stem cell virus; RRE, rev-responsive element; SIN, self-inactivating.
<b>Figure 2</b>
Figure 2
The “reverse-oriented” 0.25-kb core cHS4 insulator coupled with removal of the residual nef sequences increases transgene mRNA. (a) HeLa cells were transduced with low multiplicity of infection (MOI = 0.1) and DNA and total RNA were extracted from the cells. Enhanced green fluorescent protein (EGFP) mRNA was quantified using quantitative reverse transcription–PCR (qRT-PCR) and values, normalized to DNA copy number, are shown plotted against mean fluorescence intensity (MFI). The experiments were performed in triplicate and the error bar indicates the SEM. (b) Schematic diagram of the modified insulated vectors and the positions of the PCR primers used in this experiment. (c,d) The efficacy of the 3′end processing was assessed by qRT-PCR as described in Materials and Methods. The relative and absolute amount of read-through is indicated. The relative read-through value was calculated by dividing the U3-U5 cDNA copy number by the U3-R cDNA copy number. The experiments were performed in triplicate and the error bar indicates the SEM. *P < 0.005.
<b>Figure 3</b>
Figure 3
Reverse transcription kinetic assay for vector cDNA in target cells transduced with the parental and cHS4-insulated lentiviral vectors. 293T cells were transduced with equal amounts (80 ng of p24 Ag) of each vector stock, and DNA, including low-molecular-weight DNA, was subsequently extracted at various time points. (a) The total amount of the reverse-transcribed vector genome was measured in triplicate using a primer-probe set targeted at the human immunodeficiency virus 1 (HIV1) packaging signal sequence. Reverse-transcribed vector genome copy numbers of cells transduced with INS1(+) were significantly lower (P < 0.05), compared to cells transduced with the parental vector at 6, 12, 50, and 144 hours after transduction. (b) 2-LTR circle formation was measured using quantitative PCR. (c) The peak 2-LTR circle formation at 50 hours after transduction. All experiments were performed in triplicate. *P = 0.01. LTR, long-terminal repeat.

Similar articles

Cited by

References

    1. Aiuti A, Slavin S, Aker M, Ficara F, Deola S, Mortellaro A, et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science. 2002;296:2410–2413. - PubMed
    1. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, Nusbaum P, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science. 2000;288:669–672. - PubMed
    1. Gaspar HB, Parsley KL, Howe S, King D, Gilmour KC, Sinclair J, et al. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet. 2004;364:2181–2187. - PubMed
    1. Hacein-Bey-Abina S, Le Deist F, Carlier F, Bouneaud C, Hue C, De Villartay JP, et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med. 2002;346:1185–1193. - PubMed
    1. Hacein-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F, Wulffraat N, McIntyre E, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med. 2003;348:255–256. - PubMed

Publication types